oseltamivir ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals neuraminidase inhibitors 2001 196618-13-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ebilfumin
  • oseltamivir
  • tamvir
  • tamiflu
  • oseltamivir phosphate
Oseltamivir phosphate is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase affecting release of viral particles. The median IC50 values of oseltamivir against influenza A/H1N1, influenza A/H3N2, and influenza B clinical isolates were 2.5 nM (range 0.93-4.16 nM, N=74), 0.96 nM (range 0.13 - 7.95 nM, N=774), and 60 nM (20-285 nM, N=256), respectively, in a neuraminidase assay with a fluorescently labeled MUNANA substrate. Although oseltamivir was suggested as a potential treatment and included in various antiviral regimens used during the early stages of the COVID-19 pandemic, the drug does not appear to have in vitro activity against SARS-CoV-2 and there are no data to support the use of oseltamivir or other neuraminidase inhibitors in the treatment of COVID-19.
  • Molecular weight: 312.41
  • Formula: C16H28N2O4
  • CLOGP: 2.13
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 90.65
  • ALOGS: -2.66
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 99 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 2.71 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 75 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 27, 1999 FDA ROCHE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
No adverse event 1030.14 14.08 394 16237 33184 50555309
Exposure during pregnancy 733.62 14.08 469 16162 120546 50467947
Pregnancy 629.30 14.08 267 16364 29310 50559183
Abnormal behaviour 556.91 14.08 218 16413 19440 50569053
Hallucination 210.26 14.08 151 16480 46506 50541987
Influenza 158.19 14.08 170 16461 89368 50499125
Premature delivery 140.82 14.08 91 16540 23572 50564921
Normal newborn 127.58 14.08 56 16575 6635 50581858
Enterocolitis haemorrhagic 118.18 14.08 35 16596 1322 50587171
Off label use 113.27 14.08 377 16254 474049 50114444
Acute respiratory distress syndrome 105.91 14.08 73 16558 21026 50567467
Pathogen resistance 100.07 14.08 45 16586 5644 50582849
Maternal exposure during pregnancy 91.06 14.08 177 16454 159601 50428892
Respiratory syncytial virus infection 70.03 14.08 34 16597 5068 50583425
Respiratory failure 68.50 14.08 114 16517 91067 50497426
Delirium 64.69 14.08 71 16560 38121 50550372
Seizure 60.40 14.08 125 16506 117749 50470744
Pneumonia 58.17 14.08 262 16369 378139 50210354
Pneumonia influenzal 47.65 14.08 18 16613 1449 50587044
Vomiting 45.93 14.08 283 16348 460475 50128018
Fatigue 42.19 14.08 108 16523 707493 49881000
Stevens-Johnson syndrome 41.34 14.08 43 16588 21709 50566784
Foetal exposure during pregnancy 39.77 14.08 47 16584 27312 50561181
International normalised ratio increased 39.35 14.08 59 16572 43093 50545400
Alopecia 38.80 14.08 16 16615 245031 50343462
Premature baby 38.03 14.08 38 16593 18299 50570194
Systemic lupus erythematosus 35.07 14.08 3 16628 140619 50447874
Joint swelling 32.84 14.08 20 16611 245266 50343227
Pain 32.44 14.08 91 16540 578812 50009681
Completed suicide 32.38 14.08 3 16628 131886 50456607
Loss of consciousness 32.20 14.08 91 16540 104262 50484231
Toxicity to various agents 31.86 14.08 15 16616 212484 50376009
Treatment failure 31.58 14.08 4 16627 137633 50450860
Therapeutic product effect decreased 31.11 14.08 4 16627 136046 50452447
Colitis ischaemic 30.19 14.08 25 16606 9458 50579035
Primary myelofibrosis 29.79 14.08 6 16625 41 50588452
Atelectasis 29.26 14.08 33 16598 18237 50570256
Glomerulonephritis minimal lesion 28.97 14.08 8 16623 234 50588259
Abortion spontaneous 28.40 14.08 50 16581 41722 50546771
Accidental overdose 27.47 14.08 33 16598 19500 50568993
Synovitis 27.47 14.08 4 16627 123861 50464632
Swelling 27.41 14.08 16 16615 200856 50387637
Hypoxia 27.07 14.08 55 16576 51068 50537425
Hypothermia 26.96 14.08 26 16605 11990 50576503
Infusion related reaction 26.94 14.08 11 16620 169546 50418947
Respiratory distress 26.82 14.08 41 16590 30448 50558045
Purpura senile 26.70 14.08 9 16622 520 50587973
Drug intolerance 26.47 14.08 20 16611 219084 50369409
H1N1 influenza 26.08 14.08 12 16619 1585 50586908
Iris transillumination defect 25.97 14.08 6 16625 83 50588410
Delirium febrile 25.83 14.08 5 16626 27 50588466
Bronchopleural fistula 25.05 14.08 7 16624 214 50588279
Excessive eye blinking 25.02 14.08 10 16621 936 50587557
Influenza A virus test positive 23.82 14.08 7 16624 257 50588236
Hallucination, auditory 23.67 14.08 23 16608 10705 50577788
Tarsal tunnel syndrome 22.66 14.08 8 16623 531 50587962
Rheumatoid arthritis 22.58 14.08 20 16611 202530 50385963
Toxic epidermal necrolysis 22.50 14.08 31 16600 20961 50567532
Abortion induced 22.46 14.08 21 16610 9323 50579170
Weight increased 22.43 14.08 20 16611 201871 50386622
Hepatitis fulminant 21.25 14.08 13 16618 3055 50585438
Erythema multiforme 21.10 14.08 20 16611 9030 50579463
Neonatal pneumonia 20.92 14.08 4 16627 20 50588473
Overdose 20.75 14.08 76 16555 99651 50488842
Drug effective for unapproved indication 20.61 14.08 11 16620 1998 50586495
Hepatitis infectious mononucleosis 20.57 14.08 5 16626 87 50588406
Delusion 20.27 14.08 21 16610 10548 50577945
Product use issue 20.25 14.08 12 16619 149463 50439030
Foetal growth restriction 20.12 14.08 17 16614 6610 50581883
Agitation 19.94 14.08 50 16581 53334 50535159
Peripheral swelling 19.92 14.08 23 16608 205913 50382580
Drug-induced liver injury 19.57 14.08 34 16597 28061 50560432
Tachypnoea 19.48 14.08 24 16607 14553 50573940
Vestibular disorder 19.07 14.08 9 16622 1260 50587233
Screaming 19.06 14.08 12 16619 2966 50585527
Discomfort 18.96 14.08 6 16625 108374 50480119
Infantile apnoea 18.91 14.08 8 16623 865 50587628
Hypercapnia 18.60 14.08 14 16617 4613 50583880
Right atrial dilatation 18.02 14.08 7 16624 608 50587885
Resorption bone increased 17.78 14.08 8 16623 1003 50587490
Low birth weight baby 17.67 14.08 15 16616 5866 50582627
Altered state of consciousness 17.24 14.08 28 16603 21882 50566611
Foetal death 17.05 14.08 17 16614 8163 50580330
Legionella infection 16.66 14.08 6 16625 422 50588071
Thinking abnormal 16.56 14.08 18 16613 9549 50578944
Dysphoria 16.06 14.08 13 16618 4761 50583732
Haemorrhagic diathesis 16.00 14.08 12 16619 3936 50584557
Selective eating disorder 15.95 14.08 9 16622 1823 50586670
Infective pulmonary exacerbation of cystic fibrosis 15.68 14.08 16 16615 7893 50580600
Hepatitis 15.66 14.08 33 16598 31420 50557073
Nasopharyngitis 15.18 14.08 25 16606 192902 50395591
Oliguria 15.17 14.08 16 16615 8200 50580293
Caesarean section 15.14 14.08 22 16609 15617 50572876
Injection site pain 14.91 14.08 9 16622 111015 50477478
Coronavirus infection 14.37 14.08 10 16621 2919 50585574
Placental necrosis 14.16 14.08 3 16628 27 50588466
Hallucination, visual 14.16 14.08 22 16609 16560 50571933

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal behaviour 1148.70 15.79 408 11547 22719 29539853
Normal newborn 324.96 15.79 57 11898 117 29562455
Hallucination 239.13 15.79 174 11781 44538 29518034
Off label use 238.78 15.79 430 11525 300370 29262202
Influenza 214.91 15.79 159 11796 41722 29520850
No adverse event 196.74 15.79 109 11846 17369 29545203
Delirium 187.48 15.79 143 11812 39254 29523318
Exposure during pregnancy 103.52 15.79 56 11899 8498 29554074
Pathogen resistance 97.84 15.79 53 11902 8063 29554509
Pneumonia influenzal 67.73 15.79 24 11931 1306 29561266
Hallucination, visual 59.49 15.79 49 11906 14966 29547606
Seizure 58.22 15.79 121 11834 93002 29469570
Pneumonia 54.39 15.79 264 11691 319908 29242664
Appendicolith 54.21 15.79 27 11928 3453 29559119
JC virus infection 52.63 15.79 22 11933 1875 29560697
Sleep terror 51.97 15.79 17 11938 724 29561848
Acute respiratory distress syndrome 48.75 15.79 53 11902 22882 29539690
Vomiting 47.31 15.79 190 11765 212070 29350502
Bronchopulmonary aspergillosis 46.23 15.79 39 11916 12305 29550267
Multiple organ dysfunction syndrome 38.22 15.79 81 11874 63035 29499537
Depressed level of consciousness 35.71 15.79 58 11897 36884 29525688
Nightmare 34.61 15.79 32 11923 11385 29551187
Influenza A virus test positive 33.81 15.79 9 11946 184 29562388
Appendicitis 31.36 15.79 27 11928 8752 29553820
Crying 28.91 15.79 21 11934 5330 29557242
Aspergillus infection 27.05 15.79 27 11928 10554 29552018
Hypothermia 26.28 15.79 25 11930 9214 29553358
Pyrexia 26.16 15.79 202 11753 287420 29275152
Hallucination, auditory 25.49 15.79 25 11930 9568 29553004
Fatigue 25.14 15.79 57 11898 316764 29245808
Toxic epidermal necrolysis 23.98 15.79 33 11922 18120 29544452
Agitation 23.49 15.79 59 11896 51245 29511327
Overdose 23.21 15.79 78 11877 79741 29482831
Anaemia 22.48 15.79 29 11926 200922 29361650
Lymphocyte stimulation test positive 22.41 15.79 9 11946 692 29561880
Respiratory failure 22.38 15.79 88 11867 97043 29465529
Progressive multifocal leukoencephalopathy 21.83 15.79 22 11933 8697 29553875
Congenital heart valve disorder 21.51 15.79 5 11950 57 29562515
Rash morbilliform 21.26 15.79 13 11942 2480 29560092
Ventricular fibrillation 21.24 15.79 29 11926 15804 29546768
Cardiogenic shock 21.13 15.79 32 11923 19158 29543414
Central vision loss 21.03 15.79 4 11951 15 29562557
Enterocolitis haemorrhagic 20.74 15.79 9 11946 841 29561731
H1N1 influenza 20.54 15.79 9 11946 861 29561711
Toxicity to various agents 20.53 15.79 24 11931 173637 29388935
Foetal exposure during pregnancy 19.94 15.79 43 11912 33824 29528748
Premature baby 19.29 15.79 29 11926 17251 29545321
Hepatitis fulminant 19.26 15.79 14 11941 3557 29559015
Oedema peripheral 19.07 15.79 9 11946 103548 29459024
Restlessness 19.03 15.79 33 11922 22112 29540460
Caesarean section 18.93 15.79 11 11944 1912 29560660
Accidental overdose 18.89 15.79 29 11926 17564 29545008
Neck injury 18.39 15.79 9 11946 1108 29561464
Drug resistance 18.38 15.79 32 11923 21508 29541064
Delirium febrile 18.37 15.79 4 11951 33 29562539
Drug reaction with eosinophilia and systemic symptoms 18.18 15.79 37 11918 27955 29534617
Drug ineffective for unapproved indication 17.52 15.79 25 11930 14189 29548383
Febrile convulsion 17.43 15.79 7 11948 538 29562034
Liver disorder 17.22 15.79 36 11919 27713 29534859
Weight decreased 16.63 15.79 22 11933 150883 29411689
Cholestasis 16.42 15.79 32 11923 23430 29539142
Infective pulmonary exacerbation of cystic fibrosis 16.10 15.79 16 11939 6220 29556352
Psychiatric symptom 16.08 15.79 12 11943 3172 29559400
Stevens-Johnson syndrome 16.06 15.79 26 11929 16471 29546101

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal behaviour 1470.34 13.66 528 23279 33094 64441831
No adverse event 566.01 13.66 254 23553 28307 64446618
Exposure during pregnancy 432.24 13.66 299 23508 77376 64397549
Off label use 389.47 13.66 771 23036 632035 63842890
Hallucination 376.52 13.66 268 23539 72520 64402405
Influenza 265.79 13.66 257 23550 106274 64368651
Delirium 215.39 13.66 189 23618 69005 64405920
Pathogen resistance 212.09 13.66 100 23707 12443 64462482
Acute respiratory distress syndrome 138.75 13.66 115 23692 38820 64436105
Enterocolitis haemorrhagic 124.88 13.66 41 23766 1939 64472986
Premature delivery 123.46 13.66 80 23727 18509 64456416
Seizure 108.39 13.66 209 23598 166683 64308242
Pneumonia 104.32 13.66 445 23362 559131 63915794
Pneumonia influenzal 92.90 13.66 35 23772 2487 64472438
Pregnancy 90.08 13.66 69 23738 20796 64454129
Maternal exposure during pregnancy 85.40 13.66 138 23669 95746 64379179
Respiratory syncytial virus infection 81.80 13.66 44 23763 7224 64467701
Respiratory failure 80.19 13.66 181 23626 161002 64313923
Vomiting 66.03 13.66 387 23420 550730 63924195
Fatigue 63.78 13.66 112 23695 748618 63726307
Hallucination, visual 59.78 13.66 62 23745 27772 64447153
Influenza A virus test positive 57.56 13.66 17 23790 564 64474361
Toxicity to various agents 55.10 13.66 33 23774 363480 64111445
Appendicolith 53.58 13.66 26 23781 3443 64471482
Hypothermia 49.57 13.66 48 23759 19808 64455117
Stevens-Johnson syndrome 49.28 13.66 62 23745 34187 64440738
Overdose 47.44 13.66 148 23659 159418 64315507
Loss of consciousness 47.27 13.66 141 23666 148224 64326701
International normalised ratio increased 43.97 13.66 93 23714 79074 64395851
JC virus infection 42.55 13.66 22 23785 3333 64471592
Toxic epidermal necrolysis 42.30 13.66 60 23747 37106 64437819
Depressed level of consciousness 42.18 13.66 93 23714 81343 64393582
Bronchopulmonary aspergillosis 41.86 13.66 43 23764 19042 64455883
H1N1 influenza 41.18 13.66 19 23788 2247 64472678
Accidental overdose 40.92 13.66 56 23751 33501 64441424
Completed suicide 39.00 13.66 17 23790 224397 64250528
Multiple organ dysfunction syndrome 38.78 13.66 103 23704 101310 64373615
Hallucination, auditory 38.67 13.66 39 23768 16900 64458025
Colitis ischaemic 38.42 13.66 35 23772 13379 64461546
Hepatitis fulminant 36.81 13.66 25 23782 6249 64468676
Nightmare 36.76 13.66 42 23765 20951 64453974
Lymphocyte stimulation test positive 35.90 13.66 14 23793 1092 64473833
Restlessness 35.03 13.66 57 23750 39728 64435197
Sleep terror 34.83 13.66 14 23793 1183 64473742
Aspergillus infection 34.30 13.66 36 23771 16343 64458582
Pain 33.82 13.66 99 23708 553412 63921513
Delusion 33.18 13.66 37 23770 17977 64456948
Appendicitis 32.37 13.66 32 23775 13537 64461388
Therapeutic product effect decreased 31.65 13.66 3 23804 115348 64359577
Agitation 31.03 13.66 87 23720 88280 64386645
Alopecia 29.67 13.66 12 23795 165678 64309247
Infusion related reaction 29.30 13.66 12 23795 164455 64310470
Weight increased 28.76 13.66 22 23785 213326 64261599
Atelectasis 28.09 13.66 42 23765 27224 64447701
Drug ineffective for unapproved indication 27.94 13.66 45 23762 31088 64443837
Contraindicated product administered 26.64 13.66 4 23803 107825 64367100
Delirium febrile 26.46 13.66 6 23801 67 64474858
Drug intolerance 25.83 13.66 19 23788 187973 64286952
Psychiatric symptom 25.45 13.66 20 23787 6253 64468672
Drug resistance 25.26 13.66 46 23761 35056 64439869
Hypotension 24.82 13.66 66 23741 380908 64094017
Excessive eye blinking 24.27 13.66 11 23796 1249 64473676
Synovitis 23.75 13.66 4 23803 99086 64375839
Primary myelofibrosis 23.45 13.66 6 23801 115 64474810
Screaming 22.96 13.66 15 23792 3514 64471411
Hypoxia 22.78 13.66 78 23729 88071 64386854
Iris transillumination defect 22.67 13.66 6 23801 132 64474793
Tarsal tunnel syndrome 22.26 13.66 8 23799 497 64474428
Weight decreased 22.22 13.66 45 23762 285694 64189231
Purpura senile 22.17 13.66 8 23799 503 64474422
Pyrexia 22.01 13.66 308 23499 558336 63916589
Erythema multiforme 21.91 13.66 28 23779 15673 64459252
Hypertension 21.76 13.66 39 23768 259222 64215703
Altered state of consciousness 21.59 13.66 45 23762 37857 64437068
Infective pulmonary exacerbation of cystic fibrosis 21.33 13.66 24 23783 11772 64463153
Joint swelling 21.31 13.66 29 23778 215353 64259572
Myocardial infarction 21.22 13.66 18 23789 165803 64309122
Respiratory distress 20.86 13.66 54 23753 52277 64422648
Crying 20.77 13.66 31 23776 20059 64454866
Encephalitis influenzal 20.72 13.66 3 23804 0 64474925
Central vision loss 20.63 13.66 4 23803 19 64474906
Drug effective for unapproved indication 19.93 13.66 14 23793 3694 64471231
Nasopharyngitis 19.80 13.66 26 23781 196047 64278878
Glomerulonephritis minimal lesion 19.80 13.66 8 23799 685 64474240
Swelling 19.76 13.66 18 23789 160200 64314725
Nosocomial infection 19.55 13.66 12 23795 2525 64472400
Systemic lupus erythematosus 18.89 13.66 3 23804 77609 64397316
Peripheral swelling 18.89 13.66 30 23777 209123 64265802
Product use issue 18.77 13.66 17 23790 151698 64323227
Treatment failure 18.53 13.66 10 23797 116806 64358119
Hepatic function abnormal 18.48 13.66 59 23748 64254 64410671
Cardiac failure congestive 18.19 13.66 13 23794 130567 64344358
Hepatitis infectious mononucleosis 18.09 13.66 5 23802 130 64474795
Mobility decreased 17.47 13.66 5 23802 85835 64389090
Bronchopleural fistula 17.28 13.66 7 23800 603 64474322
Liver disorder 17.24 13.66 51 23756 53300 64421625
Encephalopathy 16.94 13.66 54 23753 58765 64416160
Shock 16.85 13.66 41 23766 38199 64436726
Ventricular fibrillation 16.83 13.66 31 23776 23829 64451096
Thinking abnormal 16.75 13.66 21 23786 11535 64463390
Pneumonia bacterial 16.70 13.66 24 23783 15011 64459914
Obliterative bronchiolitis 16.54 13.66 11 23796 2654 64472271
Anaemia 16.36 13.66 78 23729 378602 64096323
Right atrial dilatation 16.30 13.66 7 23800 699 64474226
Legionella infection 16.11 13.66 7 23800 719 64474206
Resorption bone increased 15.80 13.66 8 23799 1160 64473765
Placental necrosis 15.70 13.66 3 23804 13 64474912
Injection site pain 15.64 13.66 11 23796 111397 64363528
Pulmonary mucormycosis 15.36 13.66 7 23800 805 64474120
Upper respiratory tract inflammation 15.21 13.66 12 23795 3770 64471155
Haemorrhagic diathesis 15.04 13.66 14 23793 5500 64469425
Arthralgia 14.82 13.66 99 23708 442161 64032764
Normal newborn 14.82 13.66 14 23793 5603 64469322
Injection site erythema 14.64 13.66 4 23803 70796 64404129
Mental disorder 14.59 13.66 31 23776 26414 64448511
Disseminated intravascular coagulation 14.59 13.66 35 23772 32313 64442612
Cardiogenic shock 14.54 13.66 35 23772 32392 64442533
Placental infarction 14.09 13.66 4 23803 115 64474810
Disorientation 14.07 13.66 49 23758 55779 64419146
Encephalitis 13.87 13.66 20 23787 12551 64462374

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AH02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Neuraminidase inhibitors
FDA MoA N0000175436 Neuraminidase Inhibitors
FDA EPC N0000175524 Neuraminidase Inhibitor
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:50266 Prodrugs
CHEBI has role CHEBI:52425 acetylneuraminidase inhibitors
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:83399 marine xenobiotic metabolites
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Influenza indication 6142004 DOID:8469
Coronavirus infection off-label use 186747009
Delirium contraindication 2776000
Suicidal thoughts contraindication 6471006
Acute nephropathy contraindication 58574008
Impaired cognition contraindication 386806002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.54 acidic
pKa2 7.67 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 30MG BASE TAMIFLU ROCHE N021087 July 2, 2007 RX CAPSULE ORAL Aug. 2, 2022 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS
EQ 45MG BASE TAMIFLU ROCHE N021087 July 2, 2007 RX CAPSULE ORAL Aug. 2, 2022 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS
EQ 75MG BASE TAMIFLU ROCHE N021087 Oct. 27, 1999 RX CAPSULE ORAL Aug. 2, 2022 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS
EQ 12MG BASE/ML TAMIFLU ROCHE N021246 Dec. 14, 2000 DISCN FOR SUSPENSION ORAL Aug. 2, 2022 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS
EQ 6MG BASE/ML TAMIFLU ROCHE N021246 March 21, 2011 RX FOR SUSPENSION ORAL Aug. 2, 2022 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING INFLUENZA VIRUS RESISTANCE TO OSELTAMIVIR IN IMMUNOCOMPROMISED PATIENTS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Neuraminidase Enzyme INHIBITOR Ki 8.96 CHEMBL CHEMBL
Neuraminidase Enzyme INHIBITOR IC50 8.15 CHEMBL CHEMBL
Neuraminidase Enzyme IC50 10.22 CHEMBL
Sialidase Enzyme IC50 9 CHEMBL
Neuraminidase Enzyme IC50 8.81 CHEMBL
Neuraminidase Enzyme Ki 10 CHEMBL
Neuraminidase Enzyme Ki 8.10 CHEMBL
Neuraminidase Enzyme Ki 8.31 CHEMBL
Neuraminidase Enzyme Ki 8.96 CHEMBL
Neuraminidase Enzyme IC50 8.54 CHEMBL
Neuraminidase Enzyme IC50 6.32 CHEMBL
Neuraminidase Enzyme IC50 6.10 CHEMBL
Neuraminidase Enzyme IC50 8.86 CHEMBL
Neuraminidase Enzyme IC50 8.05 CHEMBL
Neuraminidase Enzyme IC50 9.96 CHEMBL
Neuraminidase Enzyme IC50 7.82 CHEMBL
Neuraminidase Enzyme IC50 9.83 WOMBAT-PK
Neuraminidase Enzyme IC50 6.24 CHEMBL
Neuraminidase Enzyme IC50 8.10 WOMBAT-PK

External reference:

IDSource
4021189 VUID
N0000175097 NUI
D00900 KEGG_DRUG
204255-11-8 SECONDARY_CAS_RN
4021189 VANDF
4021190 VANDF
C0874161 UMLSCUI
CHEBI:7798 CHEBI
CHEBI:73139 CHEBI
G39 PDB_CHEM_ID
CHEMBL674 ChEMBL_ID
CHEMBL1229 ChEMBL_ID
CHEMBL1200340 ChEMBL_ID
DB00198 DRUGBANK_ID
D053139 MESH_DESCRIPTOR_UI
65028 PUBCHEM_CID
11427 IUPHAR_LIGAND_ID
C535162 MESH_SUPPLEMENTAL_RECORD_UI
7793 INN_ID
187227-45-8 SECONDARY_CAS_RN
20O93L6F9H UNII
449381 PUBCHEM_CID
DB02600 DRUGBANK_ID
1546279 RXNORM
247129 MMSL
31447 MMSL
8475 MMSL
d04462 MMSL
007918 NDDF
007919 NDDF
116113006 SNOMEDCT_US
386142008 SNOMEDCT_US
412261005 SNOMEDCT_US
C2713885 UMLSCUI
K6106LV5Q8 UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 0004-0800 CAPSULE 75 mg ORAL NDA 28 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 0004-0801 CAPSULE 45 mg ORAL NDA 28 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 0004-0802 CAPSULE 30 mg ORAL NDA 28 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 0004-0822 POWDER, FOR SUSPENSION 6 mg ORAL NDA 28 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0093-8180 POWDER, FOR SUSPENSION 6 mg ORAL ANDA 29 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 16714-817 CAPSULE 30 mg ORAL ANDA 25 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 16714-818 CAPSULE 45 mg ORAL ANDA 25 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 16714-819 CAPSULE 75 mg ORAL ANDA 25 sections
Oseltamivir phosphate Human Prescription Drug Label 1 27241-139 FOR SUSPENSION 6 mg ORAL ANDA 25 sections
Oseltamivir phosphate HUMAN PRESCRIPTION DRUG LABEL 1 31722-108 POWDER, FOR SUSPENSION 6 mg ORAL ANDA 29 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 31722-630 CAPSULE 30 mg ORAL ANDA 25 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 31722-631 CAPSULE 45 mg ORAL ANDA 25 sections
Oseltamivir Phosphate Human Prescription Drug Label 1 31722-632 CAPSULE 75 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-256 CAPSULE 30 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-257 CAPSULE 45 mg ORAL ANDA 25 sections
oseltamavir phosphate Human Prescription Drug Label 1 33342-258 CAPSULE 75 mg ORAL ANDA 25 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 42254-092 POWDER, FOR SUSPENSION 6 mg ORAL NDA 30 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42291-567 FOR SUSPENSION 6 mg ORAL ANDA 28 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42291-664 CAPSULE 75 mg ORAL ANDA 27 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42291-666 CAPSULE 30 mg ORAL ANDA 27 sections
OSELTAMIVIR Human Prescription Drug Label 1 46708-413 CAPSULE 30 mg ORAL ANDA 26 sections
OSELTAMIVIR Human Prescription Drug Label 1 46708-414 CAPSULE 45 mg ORAL ANDA 26 sections
OSELTAMIVIR Human Prescription Drug Label 1 46708-415 CAPSULE 75 mg ORAL ANDA 26 sections
Oseltamivir Phosphate for Oral Suspension HUMAN PRESCRIPTION DRUG LABEL 1 47781-384 POWDER, FOR SUSPENSION 6 mg ORAL ANDA 26 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 47781-468 CAPSULE 30 mg ORAL ANDA 25 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 47781-469 CAPSULE 45 mg ORAL ANDA 25 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 47781-470 CAPSULE 75 mg ORAL ANDA 25 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 50090-0662 CAPSULE 75 mg ORAL NDA 27 sections
Tamiflu HUMAN PRESCRIPTION DRUG LABEL 1 50090-1244 POWDER, FOR SUSPENSION 6 mg ORAL NDA 27 sections
Oseltamivir Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-2726 CAPSULE 75 mg ORAL ANDA 24 sections